169 results about "Human gastric carcinoma" patented technology

The invention relates to novel anti-tumor application of an alkaloid compound penicillium enol A1 from penicillium citrinum. The penicillium citrinum IBPT-5 is collected in the China Center for Type Culture Collection (CCTCC), which is located in Wuhan University and has the collection number of CCTCC NO:M2013713, on December 25, 2013. Experiments prove that the compound has better anti-tumor activity on various tumor cells, and can be used for preparing cell proliferation inhibition medicines or anti-tumor medicines for anti-tumor study, wherein tumor cells comprise human colon cancer cells SW620, human hepatoma cells Huh7, human gastric carcinoma cells BGC-823, human colon cancer cells SW480, human esophageal squamous carcinoma cells KYSE450, human esophageal cancer cells EC9706, human highly metastatic lung carcinoma cells 95-D, human hepatoma cells PLC and human gastric carcinoma cells HGC-27.

The invention discloses phellinus baumii fruit body anticancer activity polysaccharide PBPP and a preparation method thereof.The method comprises the steps that crude polysaccharide is extracted from phellinus baumii fruit body powder through ultrasonic wave assisted hot water, precipitation is conducted with ethyl alcohol, acidic polysaccharose components are separated out through DEAE ion exchange chromatography, chromatographic purification is conducted with sephair conditioning unitryl S-100, S-200 and S-400 sequentially, eluent corresponding to eluting peaks is collected, vacuum concentration is conducted, freeze vacuum drying is conducted and a product is obtained.According to the polysaccharide PBPP and the method thereof, the purity is uniform, adverse effects on growth of normal cells do not exist, obvious inhibiting effects on growth of human cervical carcinoma cells HELA and human gastric carcinoma cells SGC-7901 are achieved, and the polysaccharide PBPP can be used for developing anticancer products.

The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.

The invention discloses a preparation method of a quercetin amide derivative and application of the quercetin amide derivative in preparing an antitumor drug. The preparation method of the quercetin amide derivative comprises the following steps of: carrying out benzyl selective protection, a Williamson ether forming reaction, a DCC (Dicyclohexylcarbodiimide) condensation reaction, catalytic hydrogenation and the line by using cheap rutin as the material. The preparation method of the quercetin amide derivative can be used for realizing the orientation and efficient modification of the quercetin, and is gentle in reaction conditions, simple to operate, simple in post-treatment and convenient for industrial production. The obtained quercetin amide derivative obviously has a stronger inbibitional effect to proliferation of a human esophageal squamous carcinoma cell EC (Ethyl Cellulose)109, a human esophageal squamous carcinoma cell EC9706, a human gastric carcinoma cell SGC (Soluble Guanylyl Cyclase) 7901 and a mouse melanoma cell B16-f10 relative to the quercetin, and therefore, the quercetin amide derivative is an anti-tumor candidate compound with great potential.

The invention provides an inula wissmannian extract and preparation thereof and application in preparation of an antitumor drug. The extract is gemma alkane type sesquiterpene lactone inula wissmannian lactone methyl, ethyl, propyl, butyl and amyl or sheepear inula herb lactone. The extract has the following chemical structural formula and absolute configuration that: due to the toxicity killing function experiment of inula wissmannian lactone methyl, ethyl, propyl, butyl and amyl or sheepear inula herb lactone on human hepatoma cells HepG2, human prostatic cancer cells PC-3, human gastric carcinoma cells MGC-803, human leukemia cells K562, human nasopharynx cancer cells KB and normal human hepatocytes LO2, the result shows that the gemma alkane type sesquiterpene lactone has strong tumor cell killing function, and proliferation of tumor cells can be inhibited, so that the tumor cells are killed. The animal in-vivo experiment proves that the inula wissmannian plant extract and monomeric compounds have the anti-tumor effect and can serve as active ingredients for preparing the antitumor drug. A novel cancer treatment medicine is provided clinically, and high clinical application values and social benefits are generated.

The invention relates to a crocetin amides derivative. The crocetin amides derivative is characterized by having the following general formula: (img file='DSA00000789203800011.tif' wi='1009' he='177'/), wherein R in the formula is (img file='DSA00000789203800012.tif' wi='1529' he='751'/). The crocetin amides derivative has obvious inhibiting effect on human lung cancer cells A549 and human gastric carcinoma cells SGC7901. Therefore, the crocetin amides derivative can be applied to preparing anti-cancer drug. The invention also discloses a preparation method of the crocetin amides derivative.

The invention discloses a dominant sequence GTM of a delta 1 chain complementary determining region (CDR) 3 in human gastric cancer tissue-derived tumor-infiltrating gamma delta T lymphocytes, a T cell receptor (TCR) containing the sequence, and TCR transfected cells. The amino acid residue sequence of the GTM is shown as SEQ ID NO.1 in a sequence table. Experiments prove that GTM peptide can be specifically combined with tumor cells, tumor tissue and V delta 1 T cell ligand MICA protein; and a J.RT3-T3.5 cell platform for expressing the TCR containing the dominant sequence GTM of the delta 1 chain CDR3 in the human gastric cancer tissue-derived tumor-infiltrating gamma delta T lymphocytes on a J.RT3-T3.5 surface is established by a lentivirus expression system, gamma delta 1 tumor-infiltrating lymphocytes (TIL) and a tumor identifying and killing mechanism thereof are simulated in the cell level, the killing activity of the transfected cells TCR gamma 4 delta 1 on the tumor cells is obviously increased, and the killing effect is TCR-dependent. The invention plays an important role in the development of medicines for treating malignant tumors and the adoptive treatment of malignant tumors, and has wide application prospects.

The invention discloses a grifola frondosa mycelium anti-tumor glycoprotein and a preparation method, and belongs to the technical field of bioengineering. The glycoprotein is prepared by the following steps: using submerged fermented grifola frondosa mycelium as a raw material, homogenating and crushing, extracting with cold water, centrifuging, taking supernatant, precipitating with ammonium sulfate, dialyzing, and carrying out DEAE (diethyl-aminoethanol) -sepharose Fast Flow and superdexTM 75 prepgrad column chromatography and other steps to systematically separate and purify. The glycoprotein is a compound of polysaccharide and protein, wherein polysaccharide is 2-10% in content and composed of four monosaccharides including arabinose, fructose, mannose and glucose; the protein is 30-90% in content and composed of 17 amino acids including aspartic acid, methionine, glutamic acid and so on; the molecular weight of the glycoprotein is 30-90 KDa. The glycoprotein can inhibit growth of human gastric carcinoma cell SGC-7901 and human breast cancer cell MCF-7, and can be used for preparing a possible anti-cancer drug. Besides, the grifola frondosa mycelium anti-tumor glycoprotein can be generally applied to separation and purification of glycoprotein obtained from mycelium of various officinal and edible fungi through submerged fermentation.

The invention discloses a coumarin-modified BODIPY (boron dipyrromethene) derivative as well as preparation and an application thereof. Chemotherapy drug coumarin covalent bonds with clear curative effects are linked to a BODIPY photosensitizer for PDT (photon dynamic treatment), so that a PDT and chemotherapy combined anti-tumor drug, namely, the coumarin-modified BODIPY derivative, is obtained.Meanwhile, the coumarin-modified BODIPY derivative is taken as a research object, a human gastric carcinoma cell BGC-823 is taken as a tested cell line, the in-vitro anti-cancer activity research is carried out, an efficient anti-cancer prodrug is screened out, and a foundation is laid for PDT and chemotherapy combination of the coumarin-modified BODIPY derivative. The synthesis method of the compound is simpler, raw materials are easy to obtain, the cost is low, few side reactions exist, the yield is higher, purification is easy, and industrial production is facilitated.

The invention discloses sansevieria trifasciata saponin, a preparation method and application thereof. The method comprises the following steps of: making the sansevieria trifasciata into dry powder, extracting by using water, alcohol or methanol, extracting by using petroleum ether or ether, and extracting by using butyl alcohol or pentanol to obtain the sansevieria trifasciata total saponin extract. The method for preparing the sansevieria trifasciata saponi optimizes the process conditions, has simple operation and low cost, has low requirement on process equipment, can reduce the consumption of solvents and enhance the leaching rate. The sterilized sansevieria trifasciata has obvious inhibition function on the growth of JurKet, has no activity killing effect on human cervical carcinoma cells (HeLa) and human gastric carcinoma cells (BGC823), and has no injury to normal Chinese Hamster Ovary (CHO), and the cell grows normally without any obvious change.

The invention discloses screening of aptamers specially targeting gastric cancer cells and aptamers obtained after screening, and belongs to the fields of bioanalysis and genetic engineering. The screening method provided by the invention is based on a cell-SELEX technology, SGC 7901 cells human gastric carcinoma cells are adopted as target cells, GES-1 cells of human gastric mucosa cells are adopted as negative-screening cells; during the negative-screening, the amount, elution time and volume of eluant are continuously increased; meanwhile, the incubating time of target cells is gradually shortened, and the incubating time of negative-screening cells is properly prolonged; through screening for several times, a sequence specially bound with the gastric cancer cells and high in binding force can be obtained, namely, the aptamers for special targeted gastric cancer cells can be obtained. The sequences for the aptamers are shown in SEQ ID NO.1-NO.6, and the aptaamers have good binding force and specificity, can be bound with and target the gastric cancer cells specially, and can be used for diagnosis of gastric cancer and preparation of gastric cancer diagnosis drugs.

The invention relates to the field of medicinal chemistry and particularly relates to hydroxamic acid compounds and application thereof in preparation of medicines for inhibiting cancer cell proliferation and/or treating cancers. The hydroxamic acid compounds provided by the invention is capable of inhibiting cancer cell proliferation so as to treat cancers and especially has excellent activity of inhibiting proliferation of melanoma cell (A375), human lung cancer cell (A549), human gastric carcinoma cell (MGC80-3), human esophageal carcinoma cell (TE-1) and cell hepatoma carcinoma cell (HepG2).

The invention discloses a method for constructing a tumor xenograft model in mice immunized with gastric cancer based on an organ-like method, and an application thereof. The invention relates to a medical tumor animal model, based on an organ-like method. For the first time, the present invention employs a quasi-organ technique, that is, using a microcarrier as substrate. The composite human gastric cancer cell line SGC-7901/MKN-45 is transplanted subcutaneously into C57BL/6 mice to establish a tumor model of human gastric cancer with normal immune function. The tumor model constructed by this method has good tumorigenicity, and the tumorigenicity rate is up to 75%. The HE staining and the immunohistochemistry of the transplanted tumor accord with the characteristics of human gastric cancer. Compared with the existing immunodeficient mice transplanted tumor model, the model can better study and further clarify the mechanism of tumor occurrence and development in the normal immune system, and also provides a more valuable new animal model for the research and development of anticancer drugs. The invention is applied to the tumor model field.

The invention discloses a method of establishing animal model of an HER2 positive tumor by using a normal mouse. The method comprises the following steps: (1) cell cultivation: cultivating a human gastric carcinoma cell NCI-N87 in a cell culture medium and collecting cells in a logarithmic phase; (2) inoculation: inoculating the human gastric carcinoma cell NCI-N87 to the normal mouse; (3) evaluation: after inoculation for two weeks, the diameter of the tumor is greater than or equal to 0.6cm and the tumor formation rate is greater than or equal to 80%, showing that the animal model of the HER2 positive tumor is successively established, wherein an immunosuppressive step of the normal mouse is not included. The method of directly inoculating the normal mouse to prepare the animal model by means of the NCI-N87 is simple to operate and stable and reliable, the test cost can be greatly lowered, and many limitations of current other tumor vaccine animal models are overcome. The method of detecting the treatment potency or preventing potency of the HER2 positive tumor vaccine can be used for screening tumor vaccine candidates in a lab and has a wide application prospect.

The invention belongs to the field of medical examination, and relates to a semen momordicae extractive as well as a preparation method and anti-tumour use thereof. The semen momordicae extractive having anti-tumour activity is prepared from corresponding components separated and purified by taking high performance liquid chromatography as the method after a sample to be measured and extracted is quenched. Found from in-vitro pharmacological experiments, the semen momordicae extractive is capable of obviously inhibiting proliferation of cancer cells by inducing cell apoptosis and retarding cell growth cycle, has an obvious inhibiting effect on human gastric carcinoma cells and other tumour cells, and can be used as the active component for preparing medicines for treating solid tumours, particularly medicines for treating human gastric carcinoma, human prostatic cancer or colon cancer. The preparation method disclosed by the invention is simple, convenient, low in cost and high in yield; and the extractive is high in component purity and good in reproducibility.

The invention discloses a series of amino acid derivatives prepared by using diosgenin as a lead compound through corresponding chemical reaction. Solubility test finds that the solubility of derivatives is increased compared with the raw material medicine of diosgenin; and the pharmacological experiments prove that the diosgenin amino acid derivatives have in vitro antitumor activity, have different degrees of growth inhibition on human colon cancer cell Caco-2, human gastric carcinoma cell MGC-709, human lung adenocarcinoma cell SPC-A-1 and human neuroblastoma cell SH-SY5Y, and have anti tumor activity similar to that of a nuclear parent compound diosgenin.

The invention relates to an application of a fingerprint atlas composed of microRNAs in diagnosis and treatment of human gastric cancer. The fingerprint atlas, which is composed of a plurality of microRNAs, can quite effectively distinguish gastric cancer tissues from tissues (normal tissues) adjacent to the gastric cancer tissues; and the fingerprint atlas, which is high in sensitivity and strong in specificity, is applicable to the effective diagnosis of the gastric cancer.

The invention relates to hydroxamic acid group-containing diarylethene LSD1/HDACs double-target inhibitors, a preparation method thereof and application thereof in preparation of antitumor drugs, andbelongs to the technical field of medicinal chemistry. The compounds have a general formula shown in the specification, wherein 3-position or 4-position monosubstitution is preferred; R2 is preferablyOH, OCH3, F or H; R3 is preferably selected from H and CH2OH; R4 is preferably selected from H, CH3, F, or OCH3; R5 is preferably selected from H, OH, CH2OH, CH3, F and OCH3; X is N or CH; Y is N orCH. The compounds provided by the invention have relatively strong inhibitory activity on LSD1 and HDAC1/6, and have very good selectivity on LSD1, and the in vitro antitumor activity of the multiplecompounds on human colon cancer HCT-116 cell strains and human gastric cancer MGC-803 cell strains is superior to that of commercially available drug SAHA. A basis is provided for research and development of LSD1/HDACs double-target inhibitor drugs, and the compounds can be used as candidates for further development or lead compounds for development of antitumor treatment drugs.

The invention provides a pyridine compound WXSA-051B which is designed and synthesized for aiming at an enzyme active site to inhibit RBP2 enzyme activity, and also provides a preparation method of the pyridine compound. Tests prove that the compound can obviously increase the level of H3K4me3 protein in a human gastric cancer cell BGC-823, has an obvious effect of inhibiting RBP2 enzyme activity,and can reduce the migration ability of the human gastric cancer cell BGC-823. The compound provided by the invention can be used as a gastric cancer inhibitor for preparing an anti-gastric cancer drug. The structure of the compound is as shown in the description.

The invention provides a water-soluble monodemethoxycurcumin derivative as shown in general formula I and a pharmaceutically acceptable salt thereof. The compound has higher water solubility as well as high antitumor activity, has a function of inhibiting human gastric carcinoma cells MGC-803, human hepatocellular carcinoma cells Bel-7402, human chronic leukemia granulocytes K562 and human glioma U87 to different extents, and can be used for preparing an antitumor medicament, and the IC50 (Inhibitory Concentration 50) reaches the level of 1 [mu]M.

The invention provides a trichothecene-type compound, namely myrothecinol roridum. The structural formula of the compound is as follows (please see the specifications for the formula), the median inhibitory concentration of the trichothecene-type compound, namely the myrothecinol roridum to human stomach cancer cell lines MGC803 is 5.4+/-0.5 [mu]m, and the median inhibitory concentration of the trichothecene-type compound, namely the myrothecinol roridum to human stomach cancer cell lines NCI-H1975 is 28.7+/-1.3 [mu]m. The trichothecene-type compound can be applied to prodrugs for treating stomach cancer and lung cancer, and the material basis is laid for the next step of drug efficacy study of drugs for stomach cancer and lung cancer.

The invention discloses application of a compound (QB) shown in a formula I in preparation of medicines for prevention and/or treatment. The MTT experiment displays that the proliferation inhibition effects of the compound QB on the four tumor cells, such as human esophageal squamous carcinoma cell EC109, the human esophageal squamous carcinoma cell EC9706, the human gastric carcinoma cell SGC7901 and mouse melanoma cell B16-F10, are obviously superior to those of quercetin. The inhibition effect of (IC50=5.201mu g/mL) on the EC109 cells is equivalent to that of fluorouracil 5-FU(IC50=5.426mu g/mL), the toxic or side effect is relatively small, and the compound is a potential antitumor candidate compound.